Hold your horses! For the kinds of FoB’s MNTA is likely to be interested in—e.g. mAbs—limited clinical trials probably will be required, at least initially. The FDA’s waiving of clinical trials is most likely for the relatively simple proteins such as the interferons, ESA’s, and variants of G-CSF.